Grifols' guidance for 2024 estimates recording an adjusted EBITDA of more than 1.8 billion euros, as well as a free cash flow of five million euros....
Grifols is a listed Catalan pharmaceutical company. The company's activity focuses on the research, development, manufacturing, and marketing of products derived from plasma (blood products), intravenous therapy...